Ronald M. Ferguson

TL;DR: PTDM is associated with an unfavorable cardiovascular risk profile that precedes the development of hyperglycemia and is an independent predictor of reduced survival in renal allograft recipients.

TL;DR: There has been an increase in the incidence of PTDM in patients transplanted recently, and that increase can be explained only partially by changes in the recipients' characteristics, postulate that this increase may be due to the introduction of better absorbed CsA formulations that result in higher blood levels and higher cumulative exposure to this diabetogenic drug.

TL;DR: Increased time ondialysis prior to renal transplantation is associated with decreased survival of transplant recipients, and increasing time on dialysis increases the prevalence of both left ventricular hypertrophy and cardiomegaly.

TL;DR: Mycophenolate mofetil has proven to be a very effective drug for the prevention of acute rejection following renal transplantation when dosed as prescribed at 2 or 3 g/d, but circumstances arise in clinical transplantation where the dose must be lowered, either to avoid drug toxicity or because of concurrent infection.

TL;DR: In this article, a multivariate analysis was performed using age, sex, blood type, race, presence of diabetes, HLA mismatch, current and maximum panel reactive antibody (PRA), time to first rejection episode, treatment of first rejection episodes, and number of rejection episodes (none, one, or more than one).